With FeNO by NIOX®, you can accurately make a difference in your community.1-3
Key highlights:
Pharmacist-delivered educational intervention was more effective in decreasing FeNO levels than usual care.1
Data shows that pharmacy intervention significantly improves patient inhaler techniques.1
You could help to provide greater patient access to asthma support, leading to improved patient outcomes for everyone in your community.2-3
Asthma: an inflammatory condition
Asthma is a chronic respiratory condition which affects around 300 million people globally.1
It is usually characterised by airway inflammation, and is defined by the history of several symptoms, such as wheeze, cough, shortness of breath, and chest tightness, all of which can vary over time and intensity.1
Asthma has many triggers, including excercise, allergen or irritant exposure, change in weather, and even viral respiratory infections.1
What is FeNO?
FeNO stands for fractional exhaled nitric oxide and correlates directly with the level of inflammation in patients’ lungs.3 FeNO is the only biomarker of airway inflammation where results are available immediately at the point-of-care.2,3
There are no blood, sweat or tears required for a patient to perform a FeNO test. Testing takes less than 2 minutes with results being accurate and reliable with NIOX VERO®.7-10
Empower patients to take back control of their asthma
FeNO testing gives patients a simple and easy to understand result.12,13 This can help them to see what is going on inside their lungs, allowing them to recognise why their asthma may be out of control.13
Pharmacists can support patients with their asthma treatment by using FeNO.11 Data shows that pharmacy intervention significantly improves patient inhaler techniques.11
Support the community
By offering FeNO testing in your pharmacy, you could become the community testing and support hub for asthma.6,13,14 Introducing FeNO could help patients understand their condition better and lead to an increase in asthma control in your local area.6,13,14
You could help to provide greater patient access to asthma support, leading to improved patient outcomes for everyone in your community.13,15
See inflammation clearly
Patients may not even be aware that they potentially have asthma, but FeNO allows you to see the inflammation clearly.4,14,16
Seeing a FeNO value helps to instill confidence with both the patient and healthcare professional.13
NIOX® Customer Support and Training
At NIOX® we are passionate about providing excellent support and training.
References:
1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2024. Available at: https://ginasthma.org/2024-report/ Accessed on: June 2024.
2. Hanania NA et al. Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions. Ann Allergy Asthma Immunol. 2018;120(4):414-418.
3. Loewenthal L et al. FeNO in asthma. Semin Respir Crit Care Med. 2022;43:635-645.
4. Busse W et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. The Lancet Respiratory Medicine. 2021;9(10):1165-73.
5. Cloutier MM et al. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC). 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217-70.
6. Petsky HL et al. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 2016;9(9).
7. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1.
8. Price D et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med. 2018;6(1):29-39.
9. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218.
10. Crater G et al. Successful fractional exhaled nitric oxide measurements with NIOX VERO using 6-and 10-s exhalation modes in children with asthma aged 4–10 years: a randomized study. Pulm Ther. 2017;3:139-48.
11. Cornia O et al. Impact of a Pharmacist-Delivered Educational Intervention on Fractional Exhaled Nitric Oxide in Patients with Asthma. Am J Respir Crit Care Med. 2018;197
.
12. Dweik RA et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-15.
13. Health Innovation Manchester. GM leads the way in Asthma care for patients through the FeNO testing model and structured reviews in community pharmacy focusing on reducing over-reliance to SABA inhalers. 2023. Available at: https://healthinnovationmanchester.com/news/gm-leads-the-way-in-asthma-care-for-patients-through-the-feno-testing-model-and-structured-reviews-in-community-pharmacy-focusing-on-reducing-over-reliance-to-saba-inhalers/. Accessed on: June 2024.
14. Asthma & Lung UK. FeNO test. Available at: https://www.asthmaandlung.org.uk/symptoms-tests-treatments/tests/feno-test. Accessed on: June 2024.
15. NHS England. Fractional Exhaled Nitric Oxide (FeNO). Available at: https://www.england.nhs.uk/aac/what-we-do/innovation-for-healthcare-inequalities-programme/rapid-uptake-products/fractional-exhaled-nitric-oxide/. Accessed on: June 2024.
16. American College of Allergy, Asthma, & Immunology (ACAAI). Asthma Symptoms. Available at: https://acaai.org/asthma/symptoms/. Accessed on: June 2024.
17. NIOX®. Product Labelling Summary NIOX VERO®. 2023.
18. NIOX®. Data on File; MKT-DOF-007. 2023.
19. Carroll WD. NIOX VERO: Individualized Asthma Management in Clinical Practice. Pulmonary Therapy. 2016;2:171-88.
20. NIOX®. Data on File; MKT-DOF-013. 2024.